<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03590730</url>
  </required_header>
  <id_info>
    <org_study_id>2017-08-027-007</org_study_id>
    <nct_id>NCT03590730</nct_id>
  </id_info>
  <brief_title>Benefits of ICD for the Primary Prevention in Patients With Valvular Cardiomyopathy</brief_title>
  <acronym>BEAT</acronym>
  <official_title>Benefits of ICD for the Primary Prevention in Patients With Valvular Cardiomyopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Keimyung University Dongsan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medtronic</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Keimyung University Dongsan Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The prevalence of valvular heart disease is on the rise along with the aging society and the
      generalization of echocardiography. Furthermore, the rheumatic valvular heart disease is much
      more prevalent in Asia than in Western countries, and the frequency of valve disease is
      higher in Asia. The effect of an implantable cardioverter defibrillator (ICD) in the primary
      prevention of sudden cardiac death in ischemic cardiomyopathy is well established and has
      become a standard of care. However, there is limited research on the effect of ICD
      implantation for primary prevention in patients with heart failure due to valvular heart
      disease. In a small study, the incidence of fatal cardiac arrhythmia was lower in patients
      with valvular cardiomyopathy (5%) who received ICD implantation for primary prevention than
      in those with ischemic cardiomyopathy. But there is also a report that the appropriate ICD
      treatment is not different from that of ischemic heart disease in valvular heart disease
      patients. Therefore, it is necessary to study the primary prevention effect of ICD on
      valvular cardiomyopathy in a larger number of patients. The purpose of this study was to
      investigate the effect of ICD on the prevention of sudden cardiac death in patients with
      heart failure due to valvular heart disease through prospective, multicenter, and
      observational studies.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 15, 2017</start_date>
  <completion_date type="Anticipated">November 15, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 15, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Appropriate ICD therapy</measure>
    <time_frame>Two year after study enrollment</time_frame>
    <description>ICD therapy that effectively terminate life-threatening arrhythmia: anti-tachycardia pacing, shock therapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>Two year after study enrollment</time_frame>
    <description>mortality was recorded and it will be classified into cardiogenic/non-cardiogenic death. Especially, arrhythmic death was recorded separately.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of inappropriate ICD therapy</measure>
    <time_frame>Two year after study enrollment</time_frame>
    <description>Inappropriately delivered ICD therapy (eg. ICD therapy delivered during sinus tachycardia)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Type of ventricular arrhythmia</measure>
    <time_frame>Two year after study enrollment</time_frame>
    <description>Analyze the type of ventricular arrhythmia</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">122</enrollment>
  <condition>Valvular Heart Disease</condition>
  <condition>Implantable Cardioverter Defibrillator</condition>
  <condition>Sudden Cardiac Death</condition>
  <condition>Primary Prevention</condition>
  <arm_group>
    <arm_group_label>Valvular heart disease</arm_group_label>
    <description>Patients with left ventricular dysfunction due to valvular heart disease who received ICD implantation for primary prevention of sudden cardiac death.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ICD implantation</intervention_name>
    <description>ICD will be implanted according to current guidelines recommendations.</description>
    <arm_group_label>Valvular heart disease</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        -  South Korean patients visiting the one of the investigator's study participating
             hospital will be enrolled.

          -  Valvular cardiomyopathy patients with left ventricular ejection fraction ≤ 35% with
             symptoms of NYHA class II, III despite optimal medical treatment for more than 3
             months according to the guideline recommendations for heart failure treatment and are
             expected to survive for more than one year.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who meet one of the following criteria:

               -  Patients who have undergone surgery for aortic valve or mitral valve disease for
                  more than 12 months

               -  Patients with severe aortic valve or mitral valve disease

          -  Patients with left ventricular ejection fraction ≤ 35% by echocardiography or other
             imaging methods

          -  US, European practice guidelines class I indication for ICD implantation

          -  Patients without evidence of ischemic heart disease (who meet one of the following
             criteria):

               -  Stress test negative

               -  Significant stenosis was not observed in coronary artery images:

        epicardial coronary stenosis &lt;70%, left main stenosis &lt;50%

          -  History of heart failure symptoms

          -  Patients who have received medication for more than 3 months according to the heart
             failure treatment guideline recommendation

        Exclusion Criteria:

          -  Patients with left ventricular dysfunction without valvular heart disease

          -  Patients who require cardiac pacing therapy due to bradycardia

          -  Heart transplant scheduled

          -  Life expectancy is less than one year
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Seongwook Han, MD, Ph D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Keimyung University Dongsan Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jongmin Hwang, MD, Ph D</last_name>
    <phone>+82-053-250-7333</phone>
    <email>dsmcep@dsmc.or.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Pusan National University Yangsan Hospital</name>
      <address>
        <city>Yangsan</city>
        <state>Gyeongsangnam-do</state>
        <zip>50612</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ki Won Hwang, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Division of Cardiology, Department of Internal Medicine, Kyungpook National University Hospital</name>
      <address>
        <city>Daegu</city>
        <zip>41944</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Myung Hwan Bae, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Division of Cardiology, Department of Internal Medicine, Yeungnam University Hospital</name>
      <address>
        <city>Daegu</city>
        <zip>42415</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dong Gu Shin, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chonnam National University Hospital</name>
      <address>
        <city>Gwangju</city>
        <zip>61469</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hyung Wook Park, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mediplex Sejong Hospital</name>
      <address>
        <city>Incheon</city>
        <zip>21080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sang Won Park, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam</city>
        <zip>13620</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Youngjin Cho, MD, Ph D</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Korea University Anam Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>02841</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jong-Il Choi, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eue-Keun Choi, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Severance Cardiovascular Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Boyoung Joung, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jun Kim, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Young Keun On, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul St. Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>06591</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yong‐Seog Oh, MD, Ph D</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>July 2, 2018</study_first_submitted>
  <study_first_submitted_qc>July 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 18, 2018</study_first_posted>
  <last_update_submitted>February 19, 2020</last_update_submitted>
  <last_update_submitted_qc>February 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Death, Sudden, Cardiac</mesh_term>
    <mesh_term>Heart Valve Diseases</mesh_term>
    <mesh_term>Death</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified individual participant data for all primary and secondary outcome measures will be made available.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Data will be available within 6 months of study completion.</ipd_time_frame>
    <ipd_access_criteria>Data access requests will be reviewed by an external independent Review Panel. Requestors will be required to sign a Data Access Agreement.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

